Skip to content

Artiva Biotherapeutics, Inc. ARTV Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
-$39.92M+10.8%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$43.06M+27.8%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$50.67M-3.9%
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
-$14M+31.8%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$19.7M-49.9%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$53.01M-34.3%

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Artiva Biotherapeutics, Inc. (ARTV) reported comprehensive income (loss), net of tax, attributable to parent of -$23.64M in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Artiva Biotherapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 17.1% year-over-year, from -$20.18M to -$23.64M.
What is the long-term trend for Artiva Biotherapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 71.6% compound annual growth rate (CAGR), from -$28.41M to -$83.63M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items like foreign currency adjustments or unrealized gains on securities. It offers a more holistic view of the company's financial performance and changes in net worth than net income alone. Investors use this to assess the total impact of all financial activities on the company's overall economic position.